Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Middle East respiratory syndrome wikipedia , lookup
Hepatitis C wikipedia , lookup
West Nile fever wikipedia , lookup
Marburg virus disease wikipedia , lookup
Orthohantavirus wikipedia , lookup
Human cytomegalovirus wikipedia , lookup
Influenza A virus wikipedia , lookup
Henipavirus wikipedia , lookup
Hepatitis B wikipedia , lookup
173 CORRESPONDENCE Use of Tissue Culture–Amplified Human Immunodeficiency Virus Type 1 to Study Evolutionary Changes In Vivo To the Editor—We would like to comment on the recent report by Dykes et al. [1] regarding the evolution of the human immunodeficiency virus (HIV) type 1 env gene after treatment with nonnucleoside reverse-transcriptase inhibitors (NNRTIs) and to provide a note of caution regarding the use of tissue culture–amplified HIV-1 to study short-term viral evolution in vivo. Determining the effect of drug-resistance selection on the evolution of a linked gene, such as env, can provide information regarding the effective population size of HIV-1 in vivo and its potential compartmentalization into anatomical sites where antiviral drug activity may vary [2, 3]. Dykes et al. [1] found no significant correlation between NNRTI therapy and changes in env sequence variants using DNA heteroduplex tracking assays and therefore concluded that these treatments had little impact on HIV-1 env evolution. We offer 5 possible explanations for why their conclusion differs from those of previous studies showing significant changes in envelope gene quasi species during the early phase of virus load rebound after failed protease inhibitor monotherapies [3–5]. First, as noted by Dykes et al. [1], because the level of drug activity in various tissues may differ between classes of drugs, it is possible that the effect of NNRTI selection on the evolution of the env loci differed from that of protease inhibitor resistance selection. Second, Dykes et al. [1] analyzed the proviral quasi species in peripheral blood mononuclear cells (PBMC), whereas the other studies analyzed the plasma viral RNA quasi species [3, 4]. Proviral DNA from PBMC represent HIV-1 variants integrated at unknown times in the past; for some proviruses, this integration might have occurred as early as the acute infection stage [6–8]. Plasma viral RNA load decreases within hours of initiating antiviral therapies and is the first viral compartment to show the appearance of drug resistance mutations [6]. Therefore, viral RNA variants in plasma reflect the actively replicating virus population, whereas PBMC proviral DNA represent largely archival HIV-1 variants [6–8]. Third, the proviral quasi species analyzed by Dykes et al. were generated after in vitro activation of PBMC and tissue culture amplification of HIV-1. Although tissue culture amplification selects for the outgrowth of replication-competent variants, tissue culture is also known to rapidly perturb and often reduce the diversity of the original PBMC proviral quasi species [9, 10]. Fourth, only data collected at 2 time points within a 4-month period were analyzed. The rapid, but mostly transient, changes previously detected would not have been apparent with such sparse sample collection [3]. Last, sufficient (i.e., reproducible) sampling by polymerase chain reaction (PCR) of the quasi species was not verified, nor was the PCR input copy number quantified; thus, the extent to which the het- eroduplex tracking assay patterns reflected the composition of the quasi species under study is questionable [3, 11]. Therefore, because the variants analyzed were proviruses derived in vitro by tissue culture amplification, they may not reflect the virus population evolving in vivo under NNRTI selection. The analysis of plasma viral RNA would have been more relevant for this particular study. The origin of the drugresistant genotypes listed by Dykes et al. (table 1 [1]) was not described in the text, but if these drug-resistant genotypes were derived from plasma viral RNA, they may differ from the genotypes of the PBMC-derived samples used for the envelope analysis. Thus, because the original time of formation of the PBMC proviruses reactivated by Dykes et al. cannot be readily determined, the extent to which their sequences reflect the evolutionary changes taking place after the addition of NNRTI to failing regimen is uncertain. Laurence Doukhan and Eric L. Delwart Blood Centers of the Pacific and Department of Medicine, University of California, San Francisco References 1. Dykes C, Mootsikapun P, Dexter A, et al. Analysis of env sequence evolution in human immunodeficiency virus–infected patients receiving therapy with nonnucleoside reverse-transcriptase inhibitors. J Infect Dis 2000; 182:316–20. 2. Leigh-Brown A, Richman DD. HIV-1: gambling on the evolution of drug resistance. Nat Med 1997; 3:268–71. 3. Delwart EL, Heng P, Neumann A, Markowitz M. Rapid, transient changes at the env locus of plasma HIV-1 populations during the emergence of protease inhibitor resistance. J Virol 1998; 72:2416–21. 4. Ibanez A, Clotet B, Martinez MA. Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. J Gen Virol 2000; 81:85–95. 5. Nijhuis M, Boucher CA, Schipper P, Leitner T, Schuurman R, Albert J. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci USA 1998; 95:14441–6. 6. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117–26. 7. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295–330. 8. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183–8. 9. Delwart EL, Pan H, Sheppard HW, et al. Slower evolution of HIV-1 quasispecies during progression to AIDS. J Virol 1997; 71:7498–508. 10. Meyerhans A, Cheynier R, Albert J, et al. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 1989; 58: 901–10. 11. Delwart EL, Gordon CJ. Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods 1997; 12:348–54. Reprints or correspondence: Dr. Eric L. Delwart, Blood Centers of the Pacific, Dept. of Medicine, University of California, San Francisco, 270 Masonic Ave., San Francisco, CA 94118 ([email protected]). The Journal of Infectious Diseases 2001; 183:173 q 2001 by the Infectious Diseases Society of America. All rights reserved. 0022-1899/2001/18301-0026$02.00